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Abstract
Type-2 immunity elicits tissue repair and homeostasis, however dysregulated type-2
responses cause aberrant tissue remodelling, as observed in asthma. Severe respiratory
viral infections in infancy predispose to later asthma, however, the processes that mediate
tissue damage-induced type-2 inflammation and the origins of airway remodelling remain ill-
defined. Here, using a preclinical mouse model of viral bronchiolitis, we find that increased
epithelial and mesenchymal high-mobility group box 1 (HMGB1) expression is associated
with increased numbers of IL-13-producing type-2 innate lymphoid cell (ILC2s) and the
expansion of the airway smooth muscle (ASM) layer. Anti-HMGB1 ablated lung ILC2 num-
bers and ASM growth in vivo, and inhibited ILC2-mediated ASM cell proliferation in a co-cul-
ture model. Furthermore, we identified that HMGB1/RAGE (receptor for advanced glycation
endproducts) signalling mediates an ILC2-intrinsic IL-13 auto-amplification loop. In sum-
mary, therapeutic targeting of the HMGB1/RAGE signalling axis may act as a novel asthma
preventative by dampening ILC2-mediated type-2 inflammation and associated ASM
remodelling.
Author summary
Asthma can start at any time in life, although most often begins in early childhood.
Wheezy viral bronchiolitis is a major independent risk factor for subsequent asthma.
However, key knowledge gaps exist in relation to the sequelae of severe viral bronchiolitis
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and the pathogenic processes that promote type-2 inflammation and airway wall remodel-
ling, cardinal features of asthma. Our study addresses this gap by identifying high-mobil-
ity group box 1 as a pathogenic cytokine that contributes to group 2 innate lymphoid cell-
induced airway smooth muscle growth.
Introduction
Asthma can start at any time in life, although most often begins in early childhood [1]. Wheezy
viral bronchiolitis is a major independent risk factor for subsequent asthma [2], yet key knowl-
edge gaps exist in relation to the pathogenic processes that link the two diseases. As the pri-
mary site of viral replication and a rich source of type-2 ‘instructive’ mediators (e.g. IL-33), the
airway epithelium is now recognised to be pivotal to disease inception through the local activa-
tion of type-2 innate lymphoid cells (ILC2) and mucosal dendritic cells. IL-33 is thought to be
the main driver of ILC2 expansion and activation, however a growing body of evidence is
beginning to implicate high-mobility group box 1 (HMGB1), another nuclear alarmin whose
extracellular expression correlates with asthma severity [3–5]. In preclinical models of allergic
asthma, anti-HMGB1 or genetic ablation of RAGE (receptor for advanced glycation endpro-
ducts), one of the receptors ligated by HMGB1, is protective [6–8]. Intriguingly, anti-HMGB1
or RAGE deficiency also diminishes IL-33-induced type-2 inflammation [6,9], suggesting that
the HMGB1/RAGE axis contributes to a feed-forward circuit that amplifies type-2 inflamma-
tion. However, whether this pathway relates to ILC2 activation remains unknown.
One of the teleological roles of type-2 inflammation is to mediate wound repair [10,11]. For
example, ILC2s can promote re-epithelialisation of the airway mucosa following viral infection
or helminth infestation [12,13]. However, ILC2s can promote aberrant tissue repair, as
observed in pulmonary fibrosis and liver fibrosis [14,15]. Curiously, it is not known whether
ILC2s contribute to airway smooth muscle (ASM) remodelling, a cardinal feature of asthma
and one of the main contributing factors to airway narrowing, loss of lung function, and air-
ways hyperreactivity. Notably, structural alterations to the airway wall are evident in school-
age children with asthma [16,17], and ASM area is increased in wheezy ‘pre-asthmatic’ chil-
dren [18], highlighting the need for early intervention strategies to prevent airway remodel-
ling, which is thought to be less plastic in later life [19].
Susceptibility to severe viral infections in infancy and the later development of asthma may
stem from an impaired and/or delayed antiviral immune responses [20,21]. Indeed, a deficient
interferon (IFN)-lambda response and greater epithelial sloughing to viral infections in chil-
dren predicts later asthma persistence [22], thus linking impaired immunity to tissue damage.
Downstream of toll-like receptor 7 and other virus-sensing pattern recognition receptors, IFN
regulatory factor (IRF)7 regulates the antiviral IFN response to respiratory syncytial virus
(RSV) and rhinovirus (RV) infection [23–25]. In a recent landmark paper comparing asthma
risk in Amish (low risk) and Hutterite (4x higher risk) farm children [26], IRF7 was identified
as a differentially expressed hub gene. In another clinical study, unbiased network analysis sep-
arated exacerbating children into IRF7hi and IRF7lo phenotypes, the latter associating with a
deficient IFN response and shorter time to exacerbation recurrence [27]. Collectively, these
findings suggest that impaired antiviral immunity predisposes to the inception of later asthma,
however the pathogenic cellular and molecular processes that underpin this relationship
remain ill-defined.
In this study, to determine whether HMGB1 is a contributing factor we used a preclinical
model of neonatal viral bronchiolitis. We found that IRF7 deficiency has a profound effect on
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the airway epithelium: namely increased viral burden, nuclear-to-cytoplasmic translocation of
HMGB1, followed by epithelial sloughing into the lumen. The subsequent release of HMGB1
has a profound effect on the number and activation of lung ILC2s, which we show to promote
ASM cell proliferation in an ILC2-ASM co-culture system. Although both ILC2s and ASM
cells produce HMGB1, we show that ILC2-derived HMGB1 acts in an autocrine manner to
amplify type-2 cytokine production. Together, our findings uncover an important role for
HMGB1 in ILC2 activation and implicate ILC2s as important effectors of both type-2 inflam-
mation and ASM thickening in early-life, predisposing to later asthma.
Results
Severe viral bronchiolitis induces epithelial damage and alarmin release
To assess the effect of impaired antiviral immunity on the development of severe viral bronchi-
olitis, we inoculated WT (+/+) and IRF7-deficient (-/-) neonatal (7 day old) mice with pneumo-
nia virus of mice (PVM). As PVM is a mouse-specific pathogen (same genus as respiratory
syncytial virus; RSV) it replicates efficiently in mice (unlike hRSV) and allows for the temporal
study of host-pathogen interactions [28,29]. Compared to WT neonatal mice, viral load was
massively elevated and clearance delayed in IRF7-/- neonatal mice (Fig 1A). This was associated
with diminished production of antiviral cytokines, IFN-α (Fig 1B) and IL-12p40 (S1A Fig). As
occurs clinically, the severe bronchiolitis that developed in IRF7-/- neonatal mice was associ-
ated with greater neutrophilic inflammation, tissue oedema, and pronounced sloughing of the
airway epithelium (Fig 1C–1E). This epithelial damage was associated with elevated IL-33 and
HMGB1 levels in the bronchoalveolar lavage fluid (BALF) and lungs of IRF7-/- neonatal mice
(Fig 1F and 1G and S1B Fig). In contrast, other known inducers of type-2 inflammation, such
as IL-25 and TSLP, were below the limit of detection. Mirroring the pattern of viral load in the
epithelium, nuclear to cytoplasmic translocation of HMGB1 peaked at 7 dpi and remained ele-
vated at 10 dpi (Fig 1H). Although HMGB1 levels in BALF persisted at 14 dpi, epithelial cell
cytoplasmic HMGB1 had waned, suggesting that extracellular HMGB1 was derived from
sloughed epithelial cells or another cellular source at this time. The functional activity of
HMGB1 is affected by its oxidative state; all-thiol HMGB1 acts as a chemokine, whereas disul-
phide HMGB1 acts as a cytokine through the activation of MD-2/TLR4 [30]. Using Western
blot to interrogate the isoforms, we observed that both all-thiol and disulphide HMGB1 were
significantly elevated in the lung homogenate of infected IRF7-/- mice compared to their WT
counterparts (Fig 1I). Thus, impaired antiviral immunity predisposed to airway epithelial
damage, IL-33 release, and a sustained period of elevated HMGB1 expression.
Severe viral bronchiolitis induces ILC2 activation and ASM proliferation
IL-33 and HMGB1 can both promote type-2 inflammation. Consistent with this, we found
that BALF levels of IL-13 and IL-5, but not IL-4 (undetectable) and airway eosinophil numbers
(Fig 2A and S1C Fig) were significantly elevated at 10 dpi in IRF7-/- compared to WT mice.
This coincided with a marked increase in the numbers of ‘natural’ (Lin-, CD90+, CD45+,
CD25+, ST2+, Sca-1+) ILC2s, which increased sharply between 7 and 10 dpi, and persisted
until at least 14 dpi in the IRF7-/- mice (Fig 2B and S1D Fig). Consistent with the absence of
IL-25, ‘inflammatory’ (Lin-, CD90+, CD45+, KLRG1high, Sca-1-) ILC2s [31] were undetectable
in the lung. To assess whether the natural ILC2s were the major source of IL-13, we crossed
the IRF7-/- mice onto IL-4/IL-13 (4C13R) dual-reporter mice [31] to allow for in situ determi-
nation of cytokine production. Examination at the peak of the IL-13 response (10 dpi) revealed
that in the IRF7-/- mice,>50% of the ILC2s were positive for dsRed (reporting for IL-13
expression), whereas in the WT infected mice ~5% of ILC2s expressed dsRed (Fig 2C). At 10
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Fig 1. IRF7 deficiency impairs antiviral immunity, heightening tissue damage and alarmin release. WT (IRF7+/+, closed circle) and IRF7-/-
mice (open circle) were inoculated with PVM or vehicle at postnatal day 7 and samples collected at 3, 7, 10 and 14 days post infection (dpi). (a)
Quantification of PVM+ airway epithelial cells (AECs). (b) IFN-α protein expression in BALF. (c) Ly6G+ neutrophils in lung sections. (d)
Oedema. (e) AEC sloughing as a proportion of basement membrane (BM) length. (f) IL-33 and (g) HMGB1 protein expression in BALF. (h)
Representative micrograph (x1000 magnification) of HMGB1immunoreactivity at 7 dpi (left panel) and quantification of cytoplasmic HMGB1 in
AECs (right panel). Bars, 5 μm. (i) Electrophoretic mobility of lung homogenate loaded onto a 12% SDS-PA gel, and revealed by western blotting
using polyclonal antibody against HMGB1 in PVM-infected WT (+/+) and IRF7-/- (-/-) mice at 10 dpi (top). Quantification of band intensity
(bottom). Data are representative of n = 2 experiments with 4–8 mice in each group and are presented as mean ± SEM (a-g) or scatter plot (i). Data
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dpi, lung but not airway ILC2s were significantly higher in IRF7-/- mice compared to WT mice
(S1E Fig). Other immune cells such CD4+ and CD8+ T cells also expressed dsRed, however
their numbers were negligible as compared to ILC2s in infected IRF7-/- mice (Fig 2D). In both
were analysed by Two-way ANOVA with Tukey post hoc test (a-g) or T-test (i); �, P< 0.05; ��, P< 0.01; ���, P< 0.001 compared with the WT
control group.
https://doi.org/10.1371/journal.ppat.1008651.g001
Fig 2. IRF7 deficiency predisposes to Pneumovirus-induced type-2 inflammation and ASM growth in early-life. WT (IRF7+/+) and IRF7-/-
mice were inoculated with PVM at postnatal day 7 and endpoints assessed at the times indicated. (a) IL-13 and IL-5 protein (10 dpi) expression
in BALF. (b) ILC2 numbers in the lung (c) Expression of IL-13 (dsRed) and IL-4 (AmCyan) by ILC2 in the lungs of 4C13R IRF7+/+ and 4C13R
IRF7-/- mice at 10 dpi. Numbers in quadrants show the percentages of gated cells. Percentage of IL-13-expressing ILC2 (right panel). (d)
Numbers of IL-13-producing ILC2, CD4+ and CD8+ cells in left lung lobe at 10 dpi. (e) ASM area. (f) Active TGFβ protein expression in BALF.
(g) Representative micrograph (x400 magnification) of TGF-β1 immunoreactivity (red) in the lung at 10 dpi. Bars, 20 μm (left panels).
Quantification of TGF-β1 expression by ASM cells (right panel). Data are representative of n = 2 experiments with 4 to 8 mice in each group and
are presented as mean ± SEM (a [left], b, e) or as box-and-whisker plots showing quartiles (boxes) and range (whiskers; a [right], c [right], d, f).
Data were analysed by Two-way ANOVA with Tukey post hoc test (a [left], b, e) or One-way ANOVA with Dunnett post hoc test (a [right], f
[right[) or T-test (c [right], d); �, P< 0.05; ��, P< 0.01; ���, P< 0.001 compared with the WT control group or as indicated.
https://doi.org/10.1371/journal.ppat.1008651.g002
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strains, ILC2s were largely negative for AmCyan (reporting for IL-4; Fig 2C). Changes to the
size of ASM area can occur in the airway wall of wheezy, pre-asthmatic infants [18]. We found
an increase in ASM area and proliferation in IRF7-/- compared to WT infected mice (Fig 2E
and S1F Fig), suggesting that ASM alterations are initiated in response to a severe respiratory
infection in early-life. TGF-β is a potent ASM mitogen [32]. We found that active TGF-β levels
in BALF were significantly higher in IRF7-/- mice compared to WT mice at both 7 and 10 dpi
(Fig 2F). Probing the lung tissue for TGF-β expression by immunohistochemistry revealed the
airway epithelium and ASM (clearly evident by morphology) to be a rich source of TGF-β fol-
lowing infection, and that its expression in ASM cells was significantly greater in IRF7-/- mice
compared to WT mice (Fig 2G). Together, these data demonstrate that, in a susceptible host, a
respiratory viral infection can lead to the induction of type-2 inflammation and ASM remodel-
ling in early life.
Secondary Pneumovirus infection or cockroach allergen exposure induces
an asthma-like phenotype in IRF7-deficient mice
Frequent viral infections are associated with progression to asthma [33], which we have previ-
ously modelled in TLR7-/- mice and pDC-depleted mice [28,34]. Here, we identified that re-
infection of IRF7-/- mice (at 7 weeks of age) induces an increase in ASM area (Fig 3A), and
that this phenotype persists for at least 8 weeks (S2A Fig). Viral challenge also increased colla-
gen deposition in the airway mucosa (S2B Fig) and increased airway hyperreactivity in the
IRF7-/- mice (Fig 3B). Although this response was maximal at 7 days, it remained significantly
elevated at 21 days post viral challenge (S2C Fig), presumably as a consequence of changes to
the airway wall architecture. These responses were not associated with viral load, since the
virus was not detectable by immunohistochemistry, even at 1 dpi. However, as with the pri-
mary infection, the induction of airway remodelling coincided with increased type-2 inflam-
mation (IL-13 production, airway eosinophilia, mucus hypersecretion), which waned by 21
dpi (Fig 3C–3E). Again, the type-2 inflammation was preceded by an increase in IL-33 and
HMGB1 expression in BALF of the IRF7-/- mice (Fig 3F). Additionally, we identified that
IRF7-/- mice that had experienced severe bronchiolitis in infancy were predisposed to develop
experimental allergic asthma in later life following exposure to low-dose cockroach allergen
extract (CRE; S2D and S2E Fig). In contrast, PVM/CRE co-exposed WT mice did not develop
asthma-like pathologies (S2E Fig). Importantly, in the absence of the viral infection in early-
life, exposure to CRE alone did not induce experimental asthma in IRF7-/- mice.
Neutralisation of HMGB1 or IL-33 diminishes type-2 inflammation and
ASM growth in IRF7-/- mice
IL-33 has been implicated in ILC2 proliferation and airway remodelling; however, the contri-
bution of HMGB1 to these processes remains an open question. To investigate this, we treated
IRF7-/- mice with anti-HMGB1 (clone 2G7), which neutralises both all-thiol and disulphide
HMGB1, or an isotype-matched control (S3A Fig), then killed the mice at 10 dpi when the
pathologies associated with asthma onset were most prominent. For comparative purposes, we
treated a separate group of mice with anti-IL-33. Anti-HMGB1 decreased HMGB1 but not IL-
33 levels in BALF, whereas blockade of IL-33 lowered both HMGB1 and IL-33 (Fig 4A and
4B), suggesting that IL-33 operates upstream of HMGB1. Anti-HMGB1 and anti-IL-33 treat-
ment of IRF7-/- mice decreased ILC2 numbers in the lung, type-2 cytokine responses in BALF,
and airway eosinophilia (Fig 4C and 4D and S3B Fig). Moreover, both treatments arrested
ASM growth (Fig 4E), an effect that was associated with lower TGF-β expression in the ASM
layer (Fig 4F). Of note, treatment of IRF7-/- mice with glycyrrhizin, a putative HMGB1
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antagonist, reproduced the findings observed with anti-HMGB1 (S3C–S3I Fig). Collectively,
these data indicated that in a host with impaired with antiviral immunity (i.e. IRF7-/- mice),
IL-33 and HMGB1 contribute to increased ILC2 numbers, type-2 cytokine production and the
development of ASM remodelling in response to an early-life viral infection.
Activated ILC2s from IRF7-/- mice induce ASM proliferation in vitro in an
HMGB1-dependent manner
ILC2s contribute to tissue remodelling by promoting fibrosis, collagen deposition, and epithe-
lial cell regeneration [12–15], however, they have yet to be implicated in the expansion of ASM
area, a cardinal feature of asthma. To confirm a role for ILC2s, we next developed an in vitro
co-culture assay to test whether ILC2s directly induce ASM cell proliferation. Primary tracheal
ASM cells were isolated from neonatal WT mice, loaded with a proliferation dye and cultured
in an FCS-low (0.25%) media prior to stimulation. Testing the proliferative effects of IL-33
and IL-13 (relative to 10% FCS) revealed that IL-33 is a poor mitogen (S4A Fig), whereas IL-13
is a potent mitogen; with an EC50 below the level of IL-13 detected in BALF (Fig 2A). To
Fig 3. Secondary Pneumovirus infection promotes an asthma-like pathology in IRF7-deficienct mice. WT (IRF7+/+) and IRF7-/- mice were inoculated with
PVM at postnatal day 7 and re-infected 6 weeks later. Samples were collected prior to re-infection (t = 0) and at 3, 7 and 21 dpi. (a) Representative micrograph
(x400 magnification) of α-smooth muscle actin immunoreactivity (red) in the lung at 7 dpi and ASM area quantification. Bars, 20 μm. (b) AHR at 30 mg/ml of
methacholine. (c) IL-13 protein levels in BALF. (d) Total eosinophil numbers in BALF. (e) Mucus-producing airway epithelial cells (AECs). (f) IL-33 (left) and
HMGB1 (right) protein expression in BALF at 3 dpi. Data are representative of n = 2 experiments with 4–9 mice in each group and are presented as mean ± SEM
(a ([right], b—e) or as box-and-whisker plots showing quartiles (boxes) and range (whiskers; f). Data were analyzed by Two-way ANOVA with Tukey post hoc
test (a ([right], b—e) or One-way ANOVA with Dunnett post hoc test (f); �, P< 0.05; ��, P< 0.01; ���, P< 0.001 compared with the WT control group.
https://doi.org/10.1371/journal.ppat.1008651.g003
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directly assess whether ILC2s promote ASM proliferation, we FACS-purified ILC2s from
IRF7-/- mice lungs at 10 dpi (S4B Fig). As expected, these ILC2s produced vast amounts of IL-
5, IL-9 and IL-13, but not IL-4, IFN-γ or IL-17A, when stimulated with IL-2/IL-33 but not IL-
2 alone (S4C Fig). In contrast to a recent report suggesting that stimulated ILC2s from adult
IRF7-/- mice produce less type-2 cytokine [35], we were unable to replicate this finding; IL-2/
IL-33-stimulated WT and IRF7-/- ILC2s produced equal amounts of IL-5 and IL-13 (S4D Fig).
When co-cultured at a 1:5 ratio with ASM cells, the IL-2/IL-33-stimulated ILC2s, but not IL-2/
IL-33 or unstimulated ILC2s alone, were able to promote ASM cell proliferation (Fig 5A,
upper panel). This response was associated with the production of IL-13 (Fig 5A), and was
attenuated when IL-13 was neutralised with sol-IL-13Rα2 (Fig 5A). Active TGF-β was signifi-
cantly elevated in the IL-2/IL-33-activated ILC2/ASM co-cultures and significantly decreased
when IL-13 was neutralised (Fig 5A). As anti-HMGB1 treatment attenuated ASM growth and
TGF-β expression in vivo (Fig 4), we questioned whether HMGB1 contributed to ILC2-me-
diated ASM proliferation in the co-culture system. Interestingly, HMGB1 levels were elevated
in the IL-2/IL-33-stimulated ILC2-ASM co-cultures, and were diminished when IL-13 was
neutralised (Fig 5A), implicating a role for HMGB1 downstream of IL-13. When HMGB1
was neutralised (anti-HMGB1) or antagonised from activating TLR4 (LPS-RS), ILC2-me-
diated ASM proliferation and the production of active TGF-β were diminished (Fig 5A).
Fig 4. Anti-HMGB1 diminishes type-2 inflammation and ASM growth in neonatal IRF7-/- mice. IRF7-/- mice were inoculated
with PVM as described in Fig 2, and treated with anti-HMGB1 or anti-IL-33 as described in S3 Fig. (a) HMGB1 and (b) IL-33
protein expression in BALF. (c) ILC2 numbers in lung. (d) IL-13 protein expression in BALF. (e) ASM area. (f) TGF-β1 expression
by ASM cells. Data are representative of n = 2 experiments with 4–8 mice in each group and are presented as box-and-whisker
plots showing quartiles (boxes) and range (whiskers). Data were analysed by t-test; �, P< 0.05; ��, P< 0.01; ���, P< 0.001.
https://doi.org/10.1371/journal.ppat.1008651.g004
PLOS PATHOGENS HMGB1 amplifies airway remodelling
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008651 July 13, 2020 8 / 21
Unexpectedly, both of these treatments also attenuated the production of IL-13, indicating the
existence of a feed-forward amplification loop between HMGB1/TLR4 and IL-13 (Fig 5A).
The requirement for TLR4 inferred a role for disulphide-HMGB1 [30,36]. Consistent with
this theory, stimulation of ASM cells with disulphide HMGB1, but not the non-oxidisable
mutant all-thiol HMGB1 [30], induced their proliferation (Fig 5B). As IL-13 but not IL-33
stimulated ASM cells produced HMGB1 (Fig 5C), and because IL-13-induced ASM cell prolif-
eration was attenuated by TLR4 or RAGE antagonism (S4E Fig), this implicated a key role for
ASM cell-derived HMGB1. In light of these finding, we re-examined the lung sections probed
with anti-HMGB1. Whereas vehicle-inoculated mice did not express HMGB1 in the ASM, its
expression increased incrementally over the course of infection in the ASM bundles of IRF7-/-
Fig 5. Activated ILC2s induce ASM proliferation in vitro in an HMGB1-dependent manner. (a-b) Primary ASM cells were isolated from naïve WT neonatal
mice and cultured with ILC2s (purified from the lungs of IRF7-/- mice at 10 dpi) in the presence of various stimuli as indicated. (a) ASM proliferation (indicated by
decreasing median fluorescence intensity (MFI)), IL-13, active TGFβ and HMGB1 concentration in the culture supernatant. � Compared to ASM cells cultured in
the absence of ILC2s or cytokine stimulation. (b) ASM proliferation in response to IL-13 (3 ng/ml), disulphide HMGB1 (30 ng/ml), or a non-oxidisable mutant
HMGB1 (30 ng/ml). � Compared to IL-13-stimulated ASM cells with disulphide-HMGB1-stimulated ASM cells or disulphide-HMGB1-stimulated ASM cells with
non-oxidisable mutant HMGB1-stimulated ASM cells as indicated. (c) HMGB1 protein expression in the supernatant of ASM cells cultured in the presence of IL-
33 or IL-13 as indicated. (d) Representative micrograph (x1000 magnification) of HMGB1 immunoreactivity (red) in the lung at 10 dpi, arrows indicate expression
by ASM cells. Bar, 5 μm. Quantification of HMGB1 expression by ASM cells. For panel a-d, data are representative of one experiment, performed twice with
similar results. For panel e, data are representative of n = 2 experiments with four to eight neonates in each group. Data are presented as box-and-whisker plots
showing quartiles (boxes) and range (whiskers; a-d) or as mean ± SEM (e [right]). Data were analysed by One-way ANOVA with Dunnett post hoc test (a-d) or
Two-way ANOVA with Tukey post hoc test (e ([right]; �, P< 0.05; ��, P< 0.01; ���, P< 0.001 compared to the respective control group.
https://doi.org/10.1371/journal.ppat.1008651.g005
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but not WT mice (Fig 5D), similar to the pattern of ASM growth (Fig 2E). In summary, our
findings suggest that in a genetically susceptible host (i.e. IRF7-/- mice in this context), ILC2-
produced IL-13 induces the release of HMGB1, leading to the activation of TLR4 and/or
RAGE signalling, which in turn, increases TGF-β production, ASM proliferation, and ampli-
fies the production of IL-13.
ILC2-derived HMGB1 in IRF7-/- mice acts in an autocrine manner to
amplify IL-13 production
Demonstrating that ASM cells release HMGB1 did not rule out the possibility that ILC2-der-
ived HMGB1 might contribute to ASM proliferation. Following IL-2/IL-33 stimulation of
ILC2s purified from IRF7-/- mice, HMGB1 was elevated in the cell cytoplasm and detected in
the supernatant (Fig 6A [left]), and this release was significantly diminished upon IL-13 neu-
tralisation (Fig 6A [right]). Together with our findings from the ILC2-ASM cell co-culture sys-
tem (Fig 5B), where anti-HMGB1 ablated IL-13 levels, these data suggested a feedforward loop
whereby IL-13-induced HMGB1 amplifies the production of IL-13. Consistent with this the-
ory, IL-2/IL-33-stimulated ILC2s produced IL-13 in a biphasic manner, with the second phase
occurring after the peak of HMGB1 release (Fig 6B). As we had previously shown that RAGE-/-
mice generate attenuated type-2 inflammatory responses to both viral- or allergen-triggered
experimental asthma [6,37], we speculated that HMGB1/RAGE ligation promotes type-2 cyto-
kine production by ILC2s. To determine whether ILC2s express RAGE, we used RAGE-/- mice
in which the functional Ager gene has been replaced by GFP. Compared to non-stained WT
ILC2s (grey), ILC2s derived from RAGE-/- mice (black) were GFP bright, indicating that
ILC2s express RAGE at steady state (Fig 6C). To assess the role of HMGB1 directly, we stimu-
lated lung ILC2s in culture with disulphide-HMGB1 or non-ox-HMGB1 in the presence of IL-
2 for 6 days. Non-Ox-HMGB1 but not disulphide-HMGB1 induced an increase in IL-5 and
IL-9 production. IL-13 production was numerically higher but this effect was not significant
(Fig 6D). To determine whether RAGE or HMGB1 contribute to IL-33-induced type-2 cyto-
kine expression by ILC2s, we stimulated ILC2s (isolated from the lungs of infected 4C13R
IRF7-/- mice) with IL-2/IL-33 for 4 days in the presence of anti-HMGB1, LPS-RS (a TLR4
antagonist) or FPS-ZM1 (a RAGE antagonist) [38]. The increased intensity of the dsRed signal
(IL-13 expression) following IL-2/IL-33 stimulation was diminished by anti-HMGB1 or
RAGE antagonism, but not TLR4 antagonism (Fig 6E), implicating an ILC2 intrinsic
HMGB1/RAGE signalling pathway that amplifies IL-13 production. Alterations in ILC2 cell
death or proliferation amongst the treatment groups did not account for this effect (S4F Fig).
In addition to attenuating IL-13 expression, anti-HMGB1 and RAGE antagonism ablated the
production of IL-5 and IL-9 (Fig 6F) in the culture supernatant, suggesting that HMGB1-me-
diated activation of RAGE contributes to the regulation of ILC2 type-2 cytokine production.
Finally, to confirm that RAGE contributes to the development of type-2 inflammation in
PVM-infected IRF7-/- mice, we administered the RAGE antagonist, FPS-ZM1. Consistent
with the lack of effect of RAGE deficiency on ILC2 proliferation (S4F Fig), lung ILC2 numbers
were unaffected. However, RAGE antagonism significantly decreased IL-5 levels in BALF,
diminished airway eosinophilia, and critically, prevented aberrant ASM growth in infancy
(Fig 6G–6J).
Discussion
Severe viral bronchiolitis is an independent risk factor for asthma. To elucidate novel patho-
genic processes that link the two diseases, we simulated a clinically relevant gene-environment
interaction by infecting IRF7-/- mice with PVM. In the absence of IRF7, viral burden increased
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Fig 6. HMGB1/RAGE axis amplifies ILC2 type-2 cytokine production and contributes to ASM growth in vivo. (a [left]) Lung ILC2s were purified from IRF7-/-
mice at 10 dpi and cultured with IL-2 for 4 days. Representative micrograph (x1000 magnification) of HMGB1 expression (red) in IL-33 stimulated ILC2s. Bar,
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substantially in the airway epithelium, leading to epithelial sloughing (i.e. cell death), HMGB1
release, expansion of IL-13-producing ILC2s, and ASM growth. Anti-HMGB1 decreased ILC2
numbers and IL-13 production, and attenuated ASM growth. Similarly, anti-HMGB1 attenu-
ated ILC2-induced ASM proliferation in a co-culture model. In addition to the airway epithe-
lium and underlying smooth muscle, we identified that ILC2 also release HMGB1 and that this
contributes to an IL-13-induced auto-amplification loop via the activation of RAGE. Thus, our
data suggest that by dampening type-2 inflammation and attenuating virus-associated ASM
remodelling, biologics or small molecules targeting HMGB1 and/or RAGE will serve as novel
preventatives for the treatment of asthma.
Several lines of evidence support the concept that impaired antiviral immunity in early-life
is associated with the later development of asthma. To identify novel pathogenic mechanisms
that occur consequent to defective antiviral host defence, we inoculated IRF7-/- neonatal mice
and followed host-pathogen interactions in a temporal manner. In IRF7-/- mice, the peak of
infection (7 dpi) was associated with increased nuclear-to-cytoplasmic HMGB1 translocation
in the epithelium, increased IL-33 levels in the airway lumen, and the infiltration of neutro-
phils, which can process IL-33 to a more biologically active form [39]. This response was fol-
lowed (10 dpi) by increased epithelial sloughing, elevated HMGB1 in the airway, ILC2
expansion, and growth of the underlying ASM layer. Of the lung ILC2s, approximately half
were producing IL-13, presumably as a consequence of the cytokine milieu, i.e. high alarmin
(IL-33/HMGB1) concentration in the absence of counter regulatory signals from type I IFNs
or IL-12 [34,40–42]. HMGB1 neutralisation attenuated the type-2 inflammatory response and
arrested ASM growth, suggesting a role for HMGB1 and ILC2 in the development of ASM
remodelling.
To implicate ILC2s directly, we developed an ILC2-ASM cell co-culture model. Using this
system, we demonstrated that ILC2-derived IL-13 induces ASM cell proliferation, and that
this effect is associated with increased ASM cell TGF-β expression (also elevated in vivo).
Although IL-13 is known to mediate its fibrotic effects via TGF-β[43], our findings suggest
that, in ASM cells at least, HMGB1 appears to act as an intermediary in this process. Of note,
ASM expression of HMGB1 is elevated in lung biopsies of patients with asthma [44]. Consis-
tent with a functional role for HMGB1, TLR4 blockade lowered active TGF-β expression,
attenuating ILC2-induced ASM proliferation. This suggested a linear pathway whereby IL-13
produced by ILC2s induces ASM cells to release HMGB1, which in turn, activates TLR4 to
induce TGF-β driven proliferation. However, neutralisation of HMGB1 in the co-culture sys-
tem affected the production of ‘upstream’ IL-13, raising three non-mutually exclusive possibil-
ities: (i) ASM-derived HMGB1 activates ILC2s to support IL-13 production, (ii) ASM-derived
HMGB1 activates TLR4 on ASM cells, which in turn, releases a secondary mediator that sup-
ports IL-13 production by ILC2, and (iii), HMGB1 is released by ILC2s and acts in an auto-
crine manner to amplify IL-13. In support of the latter possibility, we demonstrated that IL-2/
5 μm. (a [right]) HMGB1 levels in the culture supernatant after a 4 day culture +/- IL-33 (3 ng/ml) and +/- sIL-13Rα2 (5 μg/ml) as indicated. (b) IL-13 and HMGB1
protein expression by ILC2s. (c) RAGE expression detected by flow cytometry in lung ILC2s. (d) IL-5, IL-9 and IL-13 protein expression by lung ILC2s purified
from IRF7-/- mice cultured in IL-2 +/- difulphide-HMGB1 (30 ng/ml) or non-oxidisable mutant HMGB1 (30 ng/ml) as indicated. � Compared to IL-2-stimulated
ILC2s. (e) Lung ILC2s purified from 4C13R IRF7-/- mice were cultured in IL-2 +/- IL-33, and treated with anti-HMGB1 (Clone 2G7, 5 μg/ml), TLR4 antagonist
(LPS-RS 1 μg/ml) and RAGE antagonist (FPS-ZMI; 300 nM) as indicated. DsRed (IL-13) intensity was quantified by flow cytometry. � Compared to IL-2/IL-
33-stimulated ILC2s. (f) IL-5 and IL-9 production by ILC2s, treated as described in panel e. (g-m) IRF7-/- mice were inoculated with PVM as described in Fig 2, and
treated daily from 3–10 dpi with a RAGE antagonist (FPS-ZM1). (g) IL-33 and (h) HMGB1 protein expression in BALF. (i) Lung ILC2s, (j) IL-5 protein in BALF,
(k) Eosinophils in BALF, (l) ASM area, and (m) Quantification of TGF-β1 expression by ASM cells. For panel a-f, data are representative of one experiment,
performed twice with similar results. For panel g-m, data are representative of n = 2 experiments with 4–9 mice in each group and are presented as box-and-whisker
plots showing quartiles (boxes) and range (whiskers; a [right], d, g-m) or as mean ± SEM (b) or as scatter plot (e [right]-f). Data were analysed by One-way ANOVA
with Dunnett post hoc test (a, d, e [right]-f) or T-test (g-m); �, P< 0.05; ��, P< 0.01; ���, P< 0.001 compared to the respective control group.
https://doi.org/10.1371/journal.ppat.1008651.g006
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IL-33-stimulated ILC2s (in the absence of ASM cells) produce HMGB1 downstream of IL-13,
and that the neutralisation of HMGB1 or blockade of RAGE, but not TLR4, attenuates the pro-
duction of IL-13 by ILC2 (as assessed by dsRed intensity and IL-13 protein production). Simi-
larly, antagonism of the HMGB1/RAGE axis ablated IL-5 and IL-9 production, thus
identifying a novel autocrine role for HMGB1 in the production of type-2 cytokines by ILC2s.
We also demonstrated that non-oxidisable HMGB1 induces type-2 cytokine production by
ILC2s. A recent paper also implicated a role for RAGE downstream of IL-13 (and IL-4, IL-5),
although the nature of the RAGE ligand remained unclear, with HMGB1 not tested exhaus-
tively [45]. Consistent with a role for HMGB1/RAGE in mediating type-2 inflammation, we
found that RAGE antagonism dampened type-2 inflammation and ASM remodelling in
infected IRF7-/- mice. However, RAGE antagonism was not as effective as anti-HMGB1, sug-
gesting that HMGB1 exerts RAGE-independent pathways. Indeed, it was also noteworthy that
TLR4 antagonism diminished IL-13 production in the ILC2-ASM co-cultures, but had no
effect on IL-13 production when the ILC2s were cultured alone, suggesting that the activation
of TLR4 on ASM cells induces a factor which feeds back to the ILC2s. One possibility is TGF–
β, which supports lung ILC2 [46]. If such bidirectional crosstalk between inflammatory cells
and structural cells sustains the inflammatory response and underlies disease chronicity, then
breaking these circuits offers an opportunity for new and effective therapeutic interventions.
Asthma is a polygenic disorder, underpinned by gene-environment interactions. As indi-
vidual SNP effects on disease risk are small, we elected to use knockout mice, which we have
used previously to identify novel pathogenic mechanisms [34,37,47]. We believe this approach
is preferable to using an extremely high inoculum in WT mice that can induce non-physiologi-
cal responses and increase the potential for false positives. However, by using IRF7-/- mice, we
do not presume that our findings are relevant to all cases of viral bronchiolitis in infancy;
indeed we agree with view that there are different endotypes of bronchiolitis [48], as is now
accepted to be the case for asthma. On the other hand, we do not take the view that our find-
ings are only amenable to individuals with a genetic variant affecting IRF7, not least since exac-
erbating children can be subdivided into IRF7hi and IRF7lo phenotypes based on gene
expression [27]. In the in vitro ILC2: ASM cell co-culture model, we used exogenous IL-33
rather than encapsulate the lung cytokine microenvironment, and thus, there is no merit in
exploring whether IRF7-sufficient ILC2s would promote ASM proliferation (i.e. the phenotype
is IL-13 dependent, so an IL-33-stimulated IRF7-sufficient ILC2s will self-evidently induce
ASM proliferation).
Taken together with our previous findings, and reports from other groups, it is increasingly
apparent that HMGB1 is an important mediator in the pathogenesis of viral bronchiolitis and
asthma [4–6,8,9,44]. Intriguingly, PVM infection of RAGE-/- mice induces viral bronchiolitis
characterised by impaired antiviral immunity and ASM remodelling but not type-2 inflamma-
tion [37]. Notably, HMGB1 neutralisation or the backcrossing of RAGE-/- mice with TLR4-/-
mice protects against the development of ASM remodelling, implicating disulphide-HMGB1/
TLR4 activation in ASM remodelling. Our findings here support a role for the same ligand-
receptor pairing in mediating ILC2-induced ASM growth. In contrast, HMGB1/RAGE activa-
tion appears more critical to the amplification of type-2 inflammation.
Collectively, our findings provide a mechanistic basis to explain the effectiveness of anti-
HMGB1 treatment or RAGE deficiency in acute and chronic models of allergen- and viral-
induced experimental asthma. HMGB1/RAGE contributed to ILC2-mediated type-2 cytokine
production and type-2 inflammation, and ILC2-produced IL-13 activates a HMGB1/TLR4/
RAGE signalling pathway in ASM cells leading to increased TGF-β expression and ASM
remodelling.
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Methods
Experimental models
Animals. IRF7-/- (provided by Dr. Tadatsugu Taniguchi, University of Tokyo), RAGE-/-
(provided by Dr. Ann Marie Schmidt, NYU Langone Medical Centre) and 4C13R mice (pro-
vided by Dr. William Paul, NIH) [49] were imported and rederived at The University of
Queensland. Mice were housed under specific pathogen–free conditions, on a 12 hour con-
trolled day/night cycle with food and water available ad libitum in the University of Queens-
land or QIMR Berghofer Medical Research Institute, Australia. Mice were time-mated and
litter sizes (4–8 mixed genders pups) standardized at postnatal day 3. Neonatal mice were gen-
otyped using standard PCR and the following primers: IRF7-/- mice: mutant 5’-TCGTGCTT
TACGGTATCGCCGCTCCCGATTC-3’, common 5’-AGTAGATCCAAGCTCCCGGCTA
AGTTCGTAC-3’, WT 5’-GTGGTACCCAGTCCTGCCCTCTTTATAATCT-3’; 4C13R mice:
forward 50-GCTCCAAGGTGTACGTGAAG-30 and reverse 50-GCTTGGAGTCCACGTAG
TAG-30; and RAGE-/- mice: forward 5’-CCTGGGTGCTGGTTCTTG-3’ and revers 5’-CTGA
GGTCCGTGGCTAGG-3’. Stocks of pneumonia virus of mice (PVM) strain J3666 were pre-
pared as described previously [50]. At postnatal day 7, mice were inoculated (intranasal route)
with 2 pfu of PVM or vehicle (DMEM containing 10% v/v FCS) under isofluorane-induced
anaesthesia. For viral challenge, mice were inoculated with 100 PFU PVM at 49 days of age. For
cockroach extract (CRE) exposure at later life, mice were exposed to 1μg CRE at 49, 56, 63 and 70
days of age and euthanise 3 days later. In some experiments, mice were treated (i.p. route) with
anti-IL-33 (30 μg/g body weight, Pfizer, Inc) or anti-HMGB1 (8 μg/g body weight, clone 2G7; pro-
vided by Dr. Kevin Tracey, The Feinstein Institute for Medical Research), isotype-matched con-
trol antibody (30 μg/g body weight), glycyrrhizin (50 μg/g body weight; Calbiochem) or RAGE
antagonist (1 μg/g body weight, daily from 3 to 10 dpi; FPS-ZM1, Calbiochem).
Ethics statement
The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines in the EQUA-
TOR (Enhancing the Quality and Transparency of Health Research) Network library were fol-
lowed for this report. All animal studies were performed in accordance with the Animal Care
and Ethics Committees of the University of Queensland Animal Ethics Committee (AEC209/
13) and QIMR Berghofer Medical Research Institute Animal Ethics Committee (P2319
A1706-609M) and are consistent with guidelines provided by the Australian National Health
and Medical Research Council.
Sample extraction and processing
Following euthanasia, BAL was performed and lung lobes excised and processed as follows:
the left lung lobe was digested immediately for flow cytometry, the superior right lobe (for his-
tological analysis) was fixed in formalin neutral buffer overnight before storage in 70% ethanol,
the post-caval and inferior lobes (for protein analysis by ELISA) were pooled and snap-frozen,
and the inferior right lobe (for quantification of mRNA expression) was snap frozen. All snap
frozen lungs were stored at -80 ˚C.
Flow cytometry
Single cell suspensions of lung cells were generated as described [28]. Following Fc block, cells
were incubated with various antibodies to allow for immunophenotyping. These included:
anti-mouse CD2-FITC (RM2-5; BD Biosciences Cat# 553111, RRID:AB_394632), CD4–
AF488 (RM4-5; BD Biosciences Cat# 557667, RRID:AB_396779), CD11c–FITC (HL3; BD
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Biosciences Cat# 553801, RRID:AB_395060), CD11b–AF488 (M1/70; BD Biosciences Cat#
557672, RRID:AB_396784), B220-AF488 (RA3-6B2; BD Biosciences Cat# 557669, RRID:
AB_396781), CD3–AF488 (145-2C11; BD Biosciences Cat# 557666, RRID:AB_396778),
CD19-AF488 (6D5; BioLegend Cat# 115524, RRID:AB_493339), Gr-1–AF488 (RB6-8C5; Bio-
Legend Cat# 108419, RRID:AB_493480), NK1.1-AF488 (PK136; BioLegend Cat# 108717,
RRID:AB_493184), CD45-BV421 (30-F11; BioLegend Cat# 103133, RRID:AB_10899570), ST-
2-APC (DIH9; BioLegend Cat# 145305, RRID:AB_2561916), CD90.2-APC Cy7 (30-H12; Bio-
Legend Cat# 105311, RRID:AB_313182), Sca-1-PE (D7; BioLegend Cat# 108107, RRID:
AB_313344), CD25-BV650 (PC61; BioLegend Cat# 102037, RRID:AB_11125760), CD8-PE
(53–6.7; BioLegend Cat# 100707, RRID:AB_312746), CD4-AF750 (RM4-5; Thermo Fisher Sci-
entific Cat# MCD0427, RRID:AB_10371891). Cells were incubated with 7-AAD (eBioscience)
for 5 min at 4˚C to exclude dead cells. To detect RAGE expression in cells, RAGE-/- mice with
an EGFP insert was used, Cells were acquired using a LSR Fortessa X-20 (BD Biosciences), and
live cells analysed using FACSDiva v8 (BD Biosciences) and FlowJo v8.8 (Treestar).
Histology and Immunohistochemistry
Five micron thick lung tissue sections were stained with Periodic acid-Schiff or picrosirius red
to enumerate mucous-secreting cells and collagen respectively. Immunohistochemistry for
PVM G protein (gift from U. Buchholz, National Institutes of Health, Bethesda, MD), HMGB1
(polyclonal; Abcam Cat#ab18256, RRID:AB_444360), and Ly6G+ neutrophils (1A8; BD Biosci-
ences Cat# 551459, RRID:AB_394206) and quantification of immunoreactivity was performed
as described previously [6,28,34,51]. ASM was detected using α-smooth muscle actin (1A4;
Sigma-Aldrich Cat# A5691, RRID:AB_476746) monoclonal antibody and ASM area around
the small airways (defined as a circumference <500 μm for neonates and <800 μm for mice
>7 weeks old) was measured using Scanscope XT software and expressed as area per microm-
eter of basement membrane. AECs sloughing was measured using Scanscope XT software and
expressed as percentage of epithelial denudation of airway basement membrane [34]. Oedema
was assessed by point counting of fluid-filled airspaces [42]. To detect TGF-β1, tissue sections
were pre-treated with 10% normal goat serum then incubated with anti-TGF-β1 (polyclonal;
Abcam Cat# ab92486, RRID:AB_10562492) overnight, followed by incubation with anti-rabbit
IgG-alkaline phosphatase (Sigma-Aldrich) for 60 min. Immunoreactivity was developed with
Fast Red (Sigma-Aldrich), followed by counterstaining with Mayer’s hematoxylin. TGF-β1
expression in the ASM is measured by the fraction of the airway perimeter that has an adjacent
TGF-b immunoreactive ASM cell. For each mouse, 5 airways were measured, and the mean
value used in the graph. To identify proliferating ASM cells, lung sections were sequentially
incubated with mouse anti-α-SM actin ((1A4; Sigma-Aldrich Cat# A5691, RRID:AB_476746),
goat anti-mouse AF488 (Thermofisher), anti-PCNA-biotin (PC10; Thermo Fisher Scientific
Cat# 13–3940, RRID:AB_2533017), and streptavidin-AF647 (Thermofisher), then counter-
stained with DAPI (Sigma-Aldrich). To enumerate airway eosinophils, a cytospin of BAL cells
was generated then incubated with May-Grünwald Giemsa stain. To visualise airway epithelial
basement membrane thickening, sections were incubated with picrosirius red, and the stained
area quantified using ImageJ (NIH). Mucus was stained with periodic acid–schiff staining and
scored as the percentage of mucus-secreting AECs. Researchers who performed histological
analysis and scoring were blinded to the sample identity.
Measurement of protein expression
Cytokine concentration was measured by ELISA according to the manufacturer’s protocol.
The sensitivity of the assay (or where unavailable, the lowest standard used) is provided in
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parenthesis. IFN-α (2.38 pg/ml; PBL assay), IL-33 (15.6 pg/ml), IL-13 (1.5 pg/ml; R&D Sys-
tems), IL-9 (1.8 pg/ml), IL-12p40 (7.8 pg/ml, IL-17A (8 pg/ml), active-TGF-β1 (2.3 pg/ml) and
IFN-γ (15 pg/ml; Biolegend), IL-4 (2 pg/ml), and IL-5 (4 pg/ml; BD Biosciences) and HMGB1
(0.78 ng/ml; Chondrex).
Western Blot
Total protein in lung homogenates was determined using the Pierce BCA protein assay kit
(Thermo Fisher Scientific). Equivalent amounts of protein were loaded and separated on
4–20% Mini-PROTEAN TGX Precast Protein gels (Bio-Rad Laboratories) followed by transfer
on to a PVDF membrane (Bio-Rad Laboratories). After blocking with 5% skim milk in 0.1%
Tween 20/TBS, the membranes were probed with anti-HMGB1 (1:500, rabbit polyclonal;
Abcam Cat#ab18256, RRID:AB_444360) overnight at 4˚C, washed with TBS-T, then incubated
for 1 hr with IRDye 680RD donkey anti-rabbit IgG H+L (1:10,000, Millenium Science/Li-
Cor). Semi-quantification of the bands was performed with a LI-COR Odyssey scanner and
software (LI-COR Biosciences).
Airway function assessment
Airways resistance was measured by forced oscillation technique (Flexivent, Scireq), as
described previously [37].
ASM culture
Tracheal ASM cells were isolated from neonatal WT mice and cultured in DMEM/F-12 with
100 units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B, and 10% FBS as
described [52]. Cell purity, as assessed by alpha-smooth muscle actin staining, was greater than
98%. Experiments were performed at passage 4. 5 x 104 Cells were loaded with violet prolifera-
tion dye 450 according to the manufacturer’s instructions (BD Biosciences), and proliferation
indicated by decreasing median fluorescence intensity (MFI) was measured by flow cytometry
at day 4. ASM cells were stimulated with IL-13, IL-33 (both R&D Systems), disulphide
HMGB1 or non-oxidising HMGB1 (both HMGBiotech). For cytokine or receptor blockade,
cells were treated with sIL-13Rα2-Fc (5 μg/ml; Pfizer, Inc), LPS-RS (1 μg/ml, Invivogen), anti-
HMGB1 (clone 2G7; 5 μg/ml) or FPS-ZM-1 (300 nM; Calbiochem). Supernatants were stored
at -80ºC until analysis.
ILC2s culture and activation
At 10 dpi, the lungs of IRF7-/- or RAGE-/- mice were excised and digested using the gentleMACS
dissociation kit (Miltenyi Biotech). Natural ILC2s [Lineage- (CD45R, CD3, CD4, CD11c, CD19,
Gr-1, CD11b, CD2, NK1.1, CD49b), CD90.2+, CD45+, CD25+, ST2+, Sca-1+] were FACS-sorted
(>98% purity) and confirmed in separate studies that these ILC2s are GATA3+. ILC2s were cul-
tured at 104 cells/well in 200 μL of complete medium (RPMI-1640 with 1 mM sodium pyruvate,
10% FBS, 2 mM L-gutamine, 20 mM HEPES, 100 units/ml penicillin-streptomycin, 50 μM
2-mercaptoethanol) and stimulated with the indicated combinations of IL-2 (30 ng/ml;
ebioscience) and IL-33 (3 ng/ml) for 4 days. To determine HMGB1-induced ILC2 cytokines
production, ILC2s were cultured in IL-2 +/- disulphide-HMGB1 (30 ng/ml) or non-oxidisable
mutant HMGB1 (30 ng/ml) as indicated. For cytokine or receptor blockade, cells were treated
with soluble IL-13Rα2-Fc (5 μg/ml; Pfizer Inc), TLR4 antagonist, LPS-RS (1 μg/ml; Invivogen);
RAGE antagonist, FPS-ZM-1 (300 nM; Calbiochem) or anti-HMGB1 (clone 2G7, 5 μg/ml; Dr.
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Tracey, The Feinstein Institute for Medical Research). ILC2 proliferation and cell death was
measured by CFSE (Sigma Aldrich) and annexin V (Biolegend) respectively.
Statistical analysis
Graphical and statistical analyses were generated with GraphPad Prism (La Jolla, California).
A Student’s t-test, one-way ANOVA with a Dunnett post-hoc test, or two-way ANOVA with a
Tukey post-hoc test was applied as appropriate. A P value<0.05 was considered statistically
significant.
Supporting information
S1 Fig. PVM infection induces severe bronchiolitis, type-2 inflammation and ASM remod-
elling in IRF7 deficient mice. WT (IRF7+/+, closed circle) and IRF7-/- mice (open circle) were
inoculated with PVM or vehicle at postnatal day 7 and samples collected at 3, 7, 10 and 14 days
post infection (dpi). (a) IL-12p40 protein expression in BALF. (b) IL-33 protein expression in
lungs. (c) Eosinophils in BALF. (d) Gating strategy for ILC2s: Lineage- (CD45R, CD3, CD4,
CD11c, CD19, Gr-1, CD11b, CD2, NK1.1, CD49b), CD90.2+, CD45+, CD25+, ST2+, Sca-1+
ILC2 cells. (e) Numbers of ILC2 cells in left lung lobe and BALF in WT and IRF7-/- mice at 10
dpi. (f) Representative micrograph (x1000 magnification) of PCNA immunoreactivity (red)
and smooth muscle actin immunoreactivity (green) in the lung at 10 dpi (left), quantified as %
of ASM cells (right). Scale bar = 5 μm. Data are representative of n = 2 experiments with 3 to 8
mice in each group and are presented as mean ± SEM (a-c) or scatter plot (e) or as box-and-
whisker plots showing quartiles (boxes) and range (whiskers; f). Data were analysed by Two-
way ANOVA with Tukey post hoc test (a-d) or one-way ANOVA with Dunnett post hoc test
(f) or T-test (g); �, P< 0.05; ��, P< 0.01; ���, P < 0.001 compared with the WT control group.
(TIF)
S2 Fig. Secondary virus infection induces an asthma-like pathology: ASM remodelling,
basement membrane thickening and airway hyperreactivity. (a) Six weeks after the primary
infection, WT (IRF7+/+) and IRF7-/- mice were re-infected with PVM and ASM area assessed 8
weeks later. (b) Subepithelial collagen deposition and (c) AHR at 0, 3, 7 and 21 days post sec-
ondary infection. (d) Study design. WT (IRF7+/+) and IRF7-/- mice were either inoculated with
PVM at postnatal day 7 or exposed to cockroach allergen (CRE) 6 weeks later or both. (e)
Total ILC2 (Lineage- (CD45R, CD3, CD4, CD11c, CD19, Gr-1, CD11b, CD2, NK1.1, CD49b),
CD90.2+CD45+CD25+ST2+Sca-1+), eosinophil (Siglec F+CD11b+Ly6GintMHCII-CD3-B220-)
and CD4+ T cells (CD3+ CD4+ CD8-) numbers in BAL were identified by flow cytometry, fol-
lowed by mucus-producing airway epithelial cells (AECs) and ASM area quantification. Data
are representative of n = 2 experiments with 4 to 8 mice in each group and are presented as
box-and-whisker plots showing quartiles (boxes) and range (whiskers; a, e) or as mean ± SEM
(b-c). Data were analysed by T-test (a) or Two-way ANOVA with Tukey post hoc test (b-c) or
one-way ANOVA with Dunnett post hoc test (e). �, P < 0.05; ��, P < 0.01; ���, P< 0.001 com-
pared with the WT control group.
(TIF)
S3 Fig. Effect of various interventions on type-2 inflammation and ASM remodelling. (a)
Study design. (b) IL-5 expression in IRF7-/- mice in BALF (left) and eosinophils in BALF
(right). (c-i) Effect of glycyrrhizin on type-2 inflammation in PVM-infected IRF7-/- mice. (c)
Study design. (d) IL-33, (e) IL-5 and (f) IL-13 protein expression in IRF7-/- mice in BALF at 10
dpi. (g) ILC2s in lung. (h) Eosinophils in BALF. (i) ASM area. Data are representative of n = 2
experiments with four to eight neonates in each group and are presented as box-and-whisker
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plots showing quartiles (boxes) and range (whiskers; b, d-i). Data were analysed by T-test; �,
P< 0.05; ��, P< 0.01; ���, P < 0.001 compared with the IRF7-/- control group.
(TIF)
S4 Fig. IL-13 induces ASM proliferation. (a) Dose response curve of IL-13 or IL-33 stimu-
lated ASM proliferation. (b) ILC2 purification strategy by FACS; Lineage- gate included
CD45R, CD3, CD4, CD11c, CD19, Gr-1, CD11b, CD2, NK1.1, CD49b. The sorted cells were
positive for the following four markers: CD90.2+, CD45+, CD25+, and ST2+. (c) IL-2 +/- IL-33
stimulated IL-5, IL-9 IL-13, IFN-γ, IL-4 and IL-17A protein production by ILC2s. (d) ILC2s
numbers (left panel), IL-5 (middle panel) and IL-13 (right panel) protein production by lung
ILC2s purified from WT or IRF7-/- mice cultured with IL-2 +/- IL-33 (30 ng/ml) for four days.
(e) ASM proliferation in response to IL-13 in the presence of LPS-RS (TLR4 antagonist; left)
or FPS-ZM1 (RAGE antagonist; right). (f) Percent dead (left) or proliferating ILC2 cells in
response to anti-HMGB1 (2G7), TLR4 antagonist (LPS-RS) or RAGE antagonist (FPS-ZM1;
right). Data are representative of one experiment, performed twice with similar results. Data is
shown as mean ± SEM (a) or as box-and-whisker plots showing quartiles (boxes) and range
(whiskers; c-f). Data were analysed by Two-way ANOVA with Tukey post hoc test (a) or T test
((c) or One-way ANOVA with Dunnett post hoc test (d-f); �, P< 0.05; ��, P< 0.01; ���,
P< 0.001 compared with the respective control group.
(TIF)
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